Inhibit the protease of the modification of complement activation

Inhibit the protease of the modification of complement activation

  • CN 102,430,117 B
  • Filed: 10/20/2006
  • Issued: 07/24/2018
  • Est. Priority Date: 10/21/2005
  • Status: Active Grant
First Claim
Patent Images

1. the MT-SP1 protease or its catalytical active part of modification are in preparing the drug for the treatment of complement-mediated disorder or lesionApplication, wherein:

  • The MT-SP1 protease or its catalytical active part of the modification are in unmodified MT-SP1 scaffolding proteins enzyme or its catalysisInclude amino acid replacement in active part, the amino acid replacement is selected from the I41D and Q175L numbered based on chymotrypsin;

    Unmodified the MT-SP1 scaffolding proteins enzyme or its catalytical active part include SEQ ID NO:

    Amino shown in 2 or 10Acid sequence;

    The MT-SP1 protease or its catalytical active part of the modification containing the amino acid replacement show change forTarget substrate specificity and change for target substrate selectivity or both, wherein the target substrate is in complement pathwayComplement protein;

    AndThe MT-SP1 protease or its catalytical active part of the modification are when any one or more target with the complement pathwayWhen substrate contacts, lead to the cracking of the target substrate albumen, thus includes the complement activation quilt of the approach of the target substrateChange.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×